Notably, PARK7 is secreted by TCs into the bloodstream in many cancers and can be detected in the sera of cancer patients (reviewed in [63]); its serum levels therefore correlate with disease progression and were proposed to serve as a potential prognostic biomarker in cancer. This evidence concerns the gene PARK7 and cancer.